Table 1.

Regular Dosages for Drugs Administered in Patients with UC

Drug, Brand (Generic)	Class	Manufacturer	Mode of Administration	EU Dosage in UC	US Dosage in UC
Remicade (infliximab)	Anti-TNF therapy	Janssen Biotech	IV	5 mg/kg at 0, 2, and 6 weeks and every 8 weeks thereafter for the treatment of adult patients	5 mg/kg at 0, 2, and 6 weeks and every 8 weeks thereafter
Humira (adalimumab)		AbbVie	SC	160 mg at week 0 (given as four 40 mg injections in 1 day or as two 40 mg injections per day for 2 consecutive days) and 80 mg at week 2 (given as two 40 mg injections in 1 day) After induction treatment, the recommended dose is 40 mg every other week via SC injection	160 mg on day 1 (given in 1 day or split over 2 consecutive days), 80 mg on day 15 and 40 mg every other week starting on day 29. Discontinue in patients without evidence of clinical remission by 8 weeks (day 57)
Simponi (golimumab)		Janssen Biotech	SC	Patients with body weight <80 kg → initial dose of 200 mg, followed by 100 mg at week 2. Patients who have an adequate response should receive 50 mg at week 6 and every 4 weeks thereafter Patients with body weight ≥ 80 kg → initial dose of 200 mg, followed by 100 mg at week 2 and 100 mg every 4 weeks thereafter	200 mg initially administered by SC injection at week 0, followed by 100 mg at week 2 and 100 mg every 4 weeks thereafter
Entyvio (vedolizumab)	Integrin receptor antagonist	Takeda	IV	300 mg administered by IV infusion at 0, 2, and 6 weeks and every 8 weeks thereafter EU SmPC states that some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to IV vedolizumab 300 mg every 4 weeks	IV 300 mg infused over approximately 30 minutes at 0, 2, and 6 weeks and every 8 weeks thereafter
Xeljanz (tofacitinib)	JAK inhibitor	Pfizer	Oral	Induction: The recommended dose for induction treatment is 10 mg given orally twice daily for 8 weeks For patients who do not achieve adequate therapeutic benefit by week 8, the induction dose of 10 mg twice daily can be extended for an additional 8 weeks (16 weeks total), followed by 5 mg twice daily for maintenance Maintenance: The recommended dose for maintenance treatment is tofacitinib 5 mg orally given twice daily For patients with UC who are not at increased risk for venous thromboembolism, tofacitinib 10 mg orally twice daily may be considered if the patient experiences a decrease in response on tofacitinib 5 mg twice daily and failed to respond to alternative treatment options for UC such as anti-TNF therapy	Induction: Tofacitinib 10 mg twice daily or extended-release tofacitinib 22 mg once daily for 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response If needed, continue tofacitinib 10 mg twice daily or extended-release tofacitinib 22 mg once daily for a maximum of 16 weeks Discontinue tofacitinib 10 mg twice daily or extended-release tofacitinib 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved Maintenance: Tofacitinib 5 mg twice daily or extended-release tofacitinib 11 mg once daily For patients with loss of response during maintenance treatment, tofacitinib 10 mg twice daily or extended-release tofacitinib 22 mg once daily may be considered and limited to the shortest duration, with careful consideration of the benefits and risks for the individual patient
Stelara (ustekinumab)	IL-12/ IL-23 antagonist	Janssen Biotech	IV and SC	A single IV, weight based: ≤55 kg: 260 mg (2 vials) 56–85 kg: 390 mg (3 vials) >85 kg: 520 mg (4 vials) The first SC dose should be given at week 8 following the IV dose. After this, dosing every 12 weeks is recommended	A single IV, weight based: ≤55 kg: 260 mg (2 vials) 56–85 kg: 390 mg (3 vials) >85 kg: 520 mg (4 vials) The SC maintenance dose is 90 mg 8 weeks after the first IV dose and every 8 weeks thereafter

Abbreviations: Anti-TNF, tumor necrosis factor inhibitor; IL, interleukin; JAK, Janus kinase; SmPC, summary of product characteristics; UC, ulcerative colitis.